Peptide Research Blog | PeptideDosages.com

Dose conversion is the most common error. Researchers apply linear mg/kg scaling from rodents to humans, which overestimates human dosing by 7–12× because it ignores allometric scaling factors that account for metabolic rate differences. The FDA recommends using body surface area (BSA) conversion: a 10mg/kg dose in a 20g mouse converts to approximately 0.81mg/kg in a 70kg human. Not 10mg/kg. Skipping this adjustment leads to supra-therapeutic dosing in Phase 1, which triggers adverse events that wouldn't occur at correctly scaled doses.

Kisspeptin is notoriously unstable in plasma. Proteases degrade it within minutes unless samples are immediately stabilized with protease inhibitors (aprotinin 500 KIU/mL) and stored at −80°C. Collect blood into pre-chilled EDTA tubes containing protease inhibitor cocktail, centrifuge within 15 minutes, and snap-freeze plasma. Avoid freeze-thaw cycles. Aliquot samples before initial freezing. ELISA kits for kisspeptin have high cross-reactivity with degraded fragments, which inflates reported values. Use LC-MS/MS instead for accurate intact peptide quantification if precision is critical.

Arthralgia and peripheral edema occur in 10–15% of participants and result from GH-induced fluid retention and cartilage proliferation. Reduce dose to 1 mg daily or implement alternate-day dosing to lower peak GH levels while maintaining some lipolytic stimulus. If symptoms persist or worsen despite dose reduction, discontinue tesamorelin. These are known GH-related adverse effects that will not resolve with continued exposure. Differentiate from carpal tunnel syndrome, which presents as nocturnal hand numbness or tingling and occurs in approximately 5% of GH-treated patients due to median nerve compression from soft tissue swelling.

VIP access includes priority support for institutional documentation requests, including third-party purity certificates, endotoxin testing results, and synthesis facility compliance attestations. Standard-tier requests typically process within 7–10 business days. VIP requests receive 48-hour turnaround with direct coordination between Real Peptides' quality team and your institutional procurement or grants office. This matters during grant application deadlines or IRB review cycles where vendor qualification documentation gates protocol approval. We've seen research teams lose 3–4 week protocol approval windows waiting for standard documentation processing. VIP priority support eliminates that bottleneck and allows simultaneous vendor qualification and protocol submission rather than sequential processing.

Reduce the dose. Sedation typically manifests above 100 µg/kg in rodents, while stress-modulatory effects appear at 25–75 µg/kg. The therapeutic window for DSIP stress physiology sits between anxiolytic action (observable in elevated plus maze at 30 µg/kg) and sleep induction (EEG delta power increase at 80–100 µg/kg). Administer DSIP 30 minutes before stressor exposure rather than immediately prior. This timing allows cortisol suppression to peak while minimizing overlap with the peptide's sedative phase, which occurs 60–90 minutes post-injection. If sedation persists at low doses, confirm peptide purity via HPLC. Degraded DSIP or contaminated preparations can produce off-target CNS depression.